Controversies in the conducting of drug patch testing
- Autores: P. Araque Arroyo, Berta Ruiz León, Ana Burgos Montero, Teresa Gómez LLuch, Maria del Carmen Conde-García, Patricia Nieto-Sandoval Martín de la Sierra, Elisa Zamora Ferrer, Juan Carlos Valenzuela Gámez, Luis Alonso González Sánchez
- Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 18, Nº. 1, 2016, pág. 6
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Background: The Drug Patch Test (DPT) is useful as a tool for diagnosing delayed hypersensitivity skin reactions to medications. However, there is no consensus on concentration and vehicle for testing, which justifies the need to standardize a conducting method.
Method: Retrospective analysis of DPT performed in the Hospital Pharmacy Department of a 300-bed hospital over a period of 50 months. A method is described of conducting DPT in terms of the concentration to be tested, the formulation of the drug and the choice of vehicle to use.
Results: 122 Active Ingredients (AI) and 178 types of DPT were tested, with a total of 377 DPT prepared. For 55.8% of the tested AI, there was no clear information on concentration and vehicle at the moment of its preparation; currently, this information does not exist in 36.9% of tests requested. A total of 72.1% of DPT were prepared in petrolatum (AI insoluble/poorly soluble in water). For 27.3% of the AI for which there was information about procedure of preparation, there was controversy about whether to use the commercialized drug or pure allergen. The mean concentration of AI in the starting drug was 39% (median 25%). Twentynine percent of drugs contained ≤10% AI (≥50% AI: 35% of the drugs). The mean concentration of AI in DPT was 59% (median: 1.8%). A total of 50.1% of DPT tested had an AI concentration ≤2%.
Conclusions: This study presents action lines to improve the use of the patch test, highlighting the importance of conducting multicentre studies that standardize the procedures
